Olaparib maintenance extends PFS by estimated three years in advanced ovarian cancer
byEuropean Society for Medical OncologyTwo-year maintenance therapy with olaparib, a PARP (poly ADP ribose polymerase) inhibitor, olaparib, led to a substantial, unprecedented improvement in pro
Updated on: December 18,2023
13
Olaparib maintenance extends PFS by estimated three years in advanced ovarian cancer
byEuropean Society for Medical OncologyTwo-year maintenance therapy with olaparib, a PARP (poly ADP ribose polymerase) inhibitor, olaparib, led to a substantial, unprecedented improvement in pro
Updated on:December 18,2023
13
